(Q28270868)

4

William Schaffner

0 references

Anne Schuchat

17

Anne Schuchat

0 references

Cynthia G Whitney

1

Cynthia G Whitney

0 references

Elizabeth Zell

14

Elizabeth R Zell

0 references

Monica M Farley

3

Monica M Farley

0 references

Nancy M Bennett

10

Nancy M Bennett

0 references

Arthur Reingold

11

Arthur Reingold

0 references

Tamar Pilishvili

2

Tamar Pilishvili

0 references

Ann-Christine Nyquist

7

Ann-Christine Nyquist

0 references

Kenneth Gershman

8

Kenneth A Gershman

0 references

Marietta Vazquez

9

Marietta Vazquez

0 references

Bernard Beall

16

Bernard Beall

0 references

author name string

Allen S Craig

5

0 references

Ann Thomas

12

0 references

Mary P Glode

13

0 references

James H Jorgensen

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

15

0 references

language of work or name

English

0 references

publication date

28 October 2006

0 references

published in

The Lancet

0 references

volume

368

0 references

issue

9546

0 references

page(s)

1495-502

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969637-2

7 January 2021

Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969637-2

7 January 2021

A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969637-2

7 January 2021

Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969637-2

7 January 2021

Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969637-2

7 January 2021

Efficacy of a pneumococcal conjugate vaccine against acute otitis media

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969637-2

7 January 2021

Policy Statement: Recommendations for the Prevention of Pneumococcal Infections, Including the Use of Pneumococcal Conjugate Vaccine (Prevnar), Pneumococcal Polysaccharide Vaccine, and Antibiotic Prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969637-2

7 January 2021

Impact of childhood vaccination on racial disparities in invasive Streptococcus pneumoniae infections

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969637-2

7 January 2021

Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969637-2

7 January 2021

Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969637-2

7 January 2021

Active bacterial core surveillance of the emerging infections program network

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969637-2

7 January 2021

Physician and parent opinions. Are children becoming pincushions from immunizations?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969637-2

7 January 2021

Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969637-2

7 January 2021

Changes in invasive Pneumococcal disease among HIV-infected adults living in the era of childhood pneumococcal immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969637-2

7 January 2021

Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969637-2

7 January 2021

Concentration of antipneumococcal antibodies as a serological correlate of protection: an application to acute otitis media

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969637-2

7 January 2021

Serum serotype-specific pneumococcal anticapsular immunoglobulin g concentrations after immunization with a 9-valent conjugate pneumococcal vaccine correlate with nasopharyngeal acquisition of pneumococcus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969637-2

7 January 2021

Immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months post-natally to pre- and full-term infants

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969637-2

7 January 2021

Immunogenicity and tolerability of a heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 12 months of age

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969637-2

7 January 2021

Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969637-2

7 January 2021

Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969637-2

7 January 2021

Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969637-2

7 January 2021

Reduction in high rates of antibiotic-nonsusceptible invasive pneumococcal disease in tennessee after introduction of the pneumococcal conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969637-2

7 January 2021

Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969637-2

7 January 2021

Vaccines as tools against resistance: the example of pneumococcal conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969637-2

7 January 2021

Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969637-2

7 January 2021

10.1016/S0140-6736(06)69637-2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

17071283

1 reference

Consolidated OpenCitations Corpus – April 2017